Invasive Mould Infection clinical trials at University of California Health

1 research study open to eligible people

EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
open to eligible people ages 18 years and up
The purpose of this study is to determine if EL219 is safe and effective compared to liposomal amphotericin B (LAmB) or voricanozole for early treatment of invasive mould infections
at UC Davis

Last updated: May 1, 2026